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There  is  no standard  of care  for  older  patients  with  newly  diagnosed  acute  myeloid  leukemia  (AML)  unﬁt
for intensive  therapy,  and prognosis  with  currently  recommended  low-intensity  therapies  (decitabine,
azacitidine,  and  low-dose  cytarabine  [LDAC])  remains  poor.  One promising  strategy  is to  combine  low-
intensity  treatments  with  novel  agents.  Gemtuzumab  ozogamicin,  tipifarnib,  and  barasertib  have  been
investigated  in  phase  2/3 or 3  trials  combined  with  LDAC,  and  phase  3 trials  are  currently  investigating
sapacitabine  plus  decitabine,  and  volasertib  plus  LDAC in  AML.  This  review  discusses  current  treatment
recommendations  and  the development  of  combination  therapies  for  older  patients  unﬁt  for intensiveeywords:
cute myeloid leukemia (AML)
ombination
ow-intensity
ewly diagnosed
ovel agents
therapy.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).lder/elderly
. Introduction
Acute myeloid leukemia (AML) is the most common acute
eukemia diagnosed in adult patients, with the majority of cases
ccurring in patients aged 65 years or older, and a median age of
7 years at diagnosis [1,2]. Due to age and comorbidities, many
atients with AML are ineligible for standard induction chemother-
py and outcomes for these patients are poor. A retrospective
nalysis of cancer registry data for patients newly diagnosed with
ML between 1965 and 2003 found that fewer patients aged
60 years received chemotherapy compared with adult patients
ged <60 years (29.3% vs 59.0%; p < 0.001) [3]. The 3-year survival
or patients aged ≥60 years was 8.4% vs 28.0% for patients aged
9–59 years [3]. In a second retrospective analysis of cancer reg-
stry data between 1991 and 1996, median survival was  2 months
verall for patients with AML  aged ≥65 years [4]. The risk of death
igniﬁcantly (p < 0.001) increased as patient age increased; by 50%
n those aged 75–84 years, and by 150% in those ≥85 years com-
ared with those between the ages of 65 and 74 years. Even in older
atients who are able to tolerate intensive therapy, survival out-
omes remain poor. Single-center data for patients with AML  aged
60 years treated with frontline intensive chemotherapy between
∗ Tel.: +1 205 996 5590; fax: +1 205 975 3910.
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ttp://dx.doi.org/10.1016/j.leukres.2014.11.027
145-2126/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article un2000 and 2009 demonstrated a complete remission (CR) rate of
48%, but median survival of only 7.4 months and 5-year survival
of only 10%. The CR rate in patients aged ≥70 years was compara-
ble, but median survival was only 5.1 months. In contrast, clinical
outcomes for patients aged <60 years were much more favorable,
with a CR rate of 72%, median survival of 22.8 months, and 5-year
survival of 38% [5].
Despite improvements in outcomes for younger patients in
recent decades, there has been little progress in improving prog-
nosis for patients aged ≥60 years [3,6]. AML, especially in older
patients, remains an area of signiﬁcant unmet need necessitat-
ing novel therapeutic strategies. This review speciﬁcally focuses
on novel combination therapies currently under investigation for
older patients with AML  unﬁt for intensive therapy.
2. Currently recommended treatment options
Standard treatment for AML  comprises induction chemother-
apy and post-remission (or consolidation) therapy [7,8]. Age
60 years represents a therapeutic divergence point for both the
National Comprehensive Cancer Network (NCCN) and European
LeukemiaNet (ELN) treatment recommendations. For patients aged
<60 years with newly diagnosed AML, induction therapy with a
regimen based on standard-dose cytarabine combined with an
anthracycline is considered appropriate. Participation in clinical tri-
als (preferred option; participation in clinical trials considered the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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est management for all cancer patients, and is especially encour-
ged), addition of cladribine to a standard induction regimen, and
igh-dose cytarabine combined with an anthracycline are also rec-
mmended.
Separate guidelines have been created for patients with AML
ged ≥60 years in recognition of the poor treatment outcomes
bserved using a standard cytarabine and anthracycline induction
egimen in this group [7,8]. NCCN and ELN induction treatment
ecommendations for patients aged ≥60 years take into account
ot only chronologic age, but also the increased frequency of vari-
us factors which impact on a patient’s ability to tolerate intensive
reatment, including poor patient performance status, adverse fea-
ures (such as unfavorable cytogenetics and therapy-related AML  or
rior myelodysplastic syndromes [MDS]), and comorbidities. Cur-
ently no single standard of care exists for older patients with AML.
reatment options for induction therapy vary in intensity, and can
nclude: participation in a clinical trial, a standard cytarabine plus
nthracycline regimen, clofarabine, low-dose cytarabine (LDAC),
zacitidine, decitabine, and best supportive care. Low-intensity
reatment options currently recommended by NCCN guidelines
or the treatment of AML  in patients aged ≥60 years include
zacitidine, decitabine, and LDAC. In contrast, the ELN guide-
ines recommend standard induction therapy for patients aged
0–74 years with a performance status <2 and no comorbidities and
DAC for patients aged ≥75 years or ≥65 years with a performance
tatus of ≥2, comorbidities, or organ dysfunction [8]. Key efﬁcacy
nd safety data for these agents from pivotal phase 3 randomized
rials are summarized in Table 1 [9–11].
It is important to note that for some AML  patients (i.e.,
hose with complex karyotype, treatment-related disease, or
ntecedent hematologic disorder) the only potentially curative
reatment option is allogeneic hematopoietic stem cell transplan-
ation (HSCT), the role of which is limited in older patients due to
igniﬁcant comorbidities [7,8,12]. Nonetheless, a potentially cura-
ive reduced-intensity conditioning regimen followed by allogeneic
SCT [7,8] may  be an option for some older patients who are able
o achieve a response even with low-intensity induction therapy.
nce the disease has responded to therapy, including less intensive
reatments, the patient may  become a better candidate for such
urative approaches.
. Limitations of recommended low-intensity treatment
ptions for older patients
It is recognized that chronologic age alone should not deter-
ine treatment choice. However, advancing age is associated with
omorbidities and poor performance status, factors which may
ffect a patient’s ability to tolerate chemotherapy, and which are
redictive of early death [7,8,13]. Retrospective analyses of data
rom the Swedish Acute Leukemia Registry demonstrated that
tandard intensive chemotherapy regimens improved early death
ates and survival rates compared with supportive care in elderly
atients up to 80 years of age [14]. Long-term survival was evident
n some patients aged ≥65 years even with initially poor perfor-
ance status. A recent retrospective analysis of patients with newly
iagnosed AML  treated with intensive induction chemotherapy in
outhwest Oncology Group (SWOG) and MD Anderson Cancer Cen-
er (MDACC) trials between 1991 and 2009 (N = 3342) reported a
ecline in treatment-related mortality rates over time, possibly
s a result of improvements in best supportive care [15]. How-
ver this analysis could not exclude the possibility that more
nﬁrm older patients were not registered to SWOG and MDACC
rials during the last decade, but were instead treated with less
ntensive therapies, either on alternative clinical trials or with com-
ercially available agents. Induction mortality for patients withh 39 (2015) 183–191
AML  aged ≥55 years enrolled in clinical trials published between
1995 and 2009 has been estimated at 15–20% [12]. Consequently,
for many older patients the risk of treatment-related mortality
may  outweigh the potential transient beneﬁts of intensive ther-
apy, especially in those aged ≥75 years and those with signiﬁcant
comorbidities or poor performance status [7]. Physical and cogni-
tive function is another consideration that may  be more important
than chronologic age in predicting survival. In an assessment of
74 consecutive patients aged ≥60 years with newly diagnosed
AML  and considered ﬁt for intensive chemotherapy by standard
oncology assessment, geriatric assessments uncovered signiﬁcant
impairment and heterogeneity in physical, cognitive, and psycho-
logic health [16]. Impairment of cognitive function and objective
physical functioning were both associated with worse survival,
even after adjusting for age and other covariates [16].
Several studies have investigated prognostic markers of out-
comes following intensive chemotherapy, and have used these
to classify groups of elderly patients according to risk of poor
outcome [17–19]. For example, analysis of survival data from
the AML  11 trial identiﬁed cytogenetics, age, white blood cell
count, performance status, and type of AML  as prognostic markers
of survival after intensive chemotherapy. A risk index devel-
oped using the regression coefﬁcients was able to discriminate
patients with good, standard, and poor risk, which were associ-
ated with 1-year survival rates of 53%, 43%, and 16%, respectively
(p < 0.0001) [19]. A prognostic model combining both clinical and
molecular features has also been developed from retrospective
analysis of large cooperative group clinical trials [20]. A consensus-
based deﬁnition of unﬁtness for intensive chemotherapy has also
been proposed which comprises a set of nine criteria (includ-
ing age ≥75 years; congestive heart failure or cardiomyopathy;
pulmonary, renal, or hepatic disease; infection; mental illness;
poor performance status; and comorbidities incompatable with
chemotherapy) and could be a potential tool for selecting ther-
apy [21]. However, these models require validation in larger
studies and there remains a lack of a sufﬁcient deﬁnition for
the term ‘unﬁt for chemotherapy’, presenting a substantial bar-
rier to the development of new treatment approaches for unﬁt
patients.
There has been a lack of signiﬁcant progress in improving the
prognosis for older patients, and regardless of age most patients will
ultimately die from their disease [3,6]. For patients aged ≤55 years
with newly diagnosed AML  treated on Eastern Cooperative Oncol-
ogy Group protocols between 1973 and 1997, median survival
improved from 11.3 months (1973–1979; n = 454) to 20.6 months
(1989–1997; n = 1044), with 5-year survival increasing from 11%
to 37% over the same period [6]. In contrast, there was very little
change in outcomes for patients aged >55 years: median survival
was 3.5 months (1973–1979; n = 293) vs 8.2 months (1989–1997;
n = 533), and 5-year survival rates were 6% and 12%, respectively
[6].
In terms of survival beneﬁt, there remains much room for
improvement with all 3 low-intensity treatment options (azac-
itidine, decitabine, and LDAC), especially in comparison with
predicted life expectancy in the absence of disease [22]. A subanal-
ysis of phase 3 data for azacitidine vs conventional care regimens
from the AZA-001 trial investigating this agent in patients with
MDS  showed clinical beneﬁt for a subgroup of patients with MDS
with 20–30% blasts (AML, according to World Health Organiza-
tion [WHO] criteria; Table 1) [9]. Median overall survival (OS)
for azacitidine-treated patients was 24.5 months compared with
16.0 months for conventional care-treated patients (p = 0.005).
However, most of the patients in the conventional care regimen
in this study only received supportive care and did not have
proliferative disease. Therefore, it is not possible to extrapolate
this information to all older AML  patients. Patients who received
H.P. Erba / Leukemia Research 39 (2015) 183–191 185
Table  1
Summary of phase 3 efﬁcacy and safety data for decitabine, azacitidine, and LDAC in AML.
Agent Efﬁcacy data Safety data
Azacitidine Phase 3 AZA-001 trial in higher-risk MDS; subgroup analysis of patients with
WHO-deﬁned AML  [9]
Azacitidine (75 mg/m2/day for 7 days every 4 weeks) vs conventional care
regimens (supportive care, LDAC [20 mg/m2/day sc for 14 days every 4 weeks], or
intensive chemotherapy) in adult patients (median age, 70 years) with ≥20%
blasts (i.e., with FAB-deﬁned RAEB-t MDS and WHO-deﬁned AML; N = 113)
Survival was improved with azacitidine:
• median OS was 24.5 (95% CI: 14.6–NR) months with azacitidine vs 16.0
(11.5–17.5) months with conventional care regimens; HR = 0.47
(95% CI: 0.28–0.79); p = 0.005
•  2-year OS was  50% vs 16% (p = 0.001)
There was no difference in morphologic CR rates:
•  18% with azacitidine vs 16% with conventional care regimens (p = 0.80)
The most common grade 3/4 hematologic AEs (azacitidine
vs  conventional care regimens) were:
•  thrombocytopenia (91% vs 83%), neutropenia
(94% vs 83%), and anemia (57% vs 68%)
Patients who received azacitidine had fewer hospital
admissions vs those treated with conventional care
regimens and spent less time in hospital:
•  3.4 vs 4.3 admissions per patient year (p = 0.05)
•  26.0 vs 50.9 days in hospital (p < 0.0001)
Decitabine Phase  3 DACO-16 trial [10]
Decitabine (20 mg/m2 once daily iv for 5 days every 4 weeks) vs treatment choice
(supportive care or cytarabine [20 mg/m2 once daily sc for 10 days every 4 weeks])
in older (≥65 years) patients with newly diagnosed AML and poor- or
intermediate-risk cytogenetics (N = 485)
Primary endpoint of OS was not met  in the ﬁnal analysis:
•  median OS was 7.7 (95% CI: 6.2–9.2) months with decitabine vs 5.0
(95% CI: 4.3–6.3) months with treatment choice; HR = 0.85 (95% CI: 0.69–1.04);
p  = 0.108
Subsequent, unplanned analysis of mature survival data showed a signiﬁcant
difference in OS:
• HR = 0.82 (95% CI: 0.68–0.99); p = 0.037
CR + CRp rate was signiﬁcantly higher with decitabine:
•  17.8% with decitabine vs 7.8% with treatment choice (p = 0.001)
Drug-related AEs with decitabine were predominantly
myelosuppressive. The most common drug-related AEs
(decitabine vs cytarabine) were:
•  thrombocytopenia (27% vs 26%), anemia (21% vs 20%),
neutropenia (24% vs 15%), febrile neutropenia (24% vs 15%)
Exposure to study medication was higher with decitabine:
•  median number of treatment cycles 4.4 months with
decitabine vs 2.4 months with cytarabine
30-day mortality was similar with decitabine and
cytarabine:
•  9% with decitabine vs 8% with cytarabine
LDAC Phase  3 AML  14 trial; subgroup analysis of patients ineligible for intensive
chemotherapy [11]
LDAC (cytarabine 20 mg sc twice daily for 10 days every 4–6 weeks)  vs supportive
care  with HU in adult patients (median age, 74 years) with AML or high-risk MDS
(N = 212)
Treatment with LDAC improved OS vs HU:
•  OR = 0.60 (95% CI: 0.44–0.81); p = 0.0009
CR rate was also improved with LDAC vs HU:
•  18% vs 1%; OR = 0.15 (95% CI: 0.06–0.37); p < 0.00006
No  beneﬁt was seen with LDAC for patients with adverse cytogenetics
No substantial differences in toxicity or supportive care
requirements with LDAC vs HU were observed
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AEB-t: refractory anemia with excess blasts in transformation; sc: subcutaneously
zacitidine also had fewer hospital admissions, and spent less time
n hospital compared with those treated with conventional care
egimens. However, most of the patients in the conventional care
egimen in this study only received supportive care. Furthermore,
hese patients did not have proliferative disease and the marrow
nd blood blast percentage were <30%. Therefore, it is not possi-
le to extrapolate this information to all older patients with AML.
 phase 3 trial evaluating azacitidine in older patients with newly
iagnosed AML (≥65 years) and >30% blasts (NCT01074047) did
ot demonstrate a signiﬁcant survival beneﬁt compared with con-
entional care (10.4 vs 6.5 months; p = 0.1009) [23]. However, in
 prespeciﬁed sensitivity analysis for OS with patients censored at
he start of subsequent AML  therapy, azacitidine did demonstrate
 signiﬁcant beneﬁt (12.1 vs 6.9 months; p = 0.019).
Similarly, results from the phase 3 DACO-016 trial of decitabine
ompared with patient choice of either supportive care or LDAC
n older (≥65 years) patients with newly diagnosed AML  demon-
trated improved CR rates vs standard therapies, including LDAC
10]. However, the LDAC regimen was not identical to that used in
he Medical Research Council (MRC) trials which had shown a bene-
t over hydroxyurea [11], and the response rate reported with LDAC
n this study was lower than that seen in other reports. There was no
igniﬁcant OS beneﬁt according to the per-protocol primary anal-
sis (7.7 vs 5.0 months; p = 0.108) [10]. A subsequent, unplanned
nalysis found the survival beneﬁt with decitabine to be signiﬁcant.mission; CRp: CR with incomplete platelet recovery; FAB: French-American-British;
myelodysplastic syndromes; NR: not reached; OR: odds ratio; OS: overall survival;
O: World Health Organization.
Based on the data from this trial, decitabine was approved in 2012
by the European Medicines Agency for the treatment of patients
≥65 years with AML  ineligible for induction therapy [24]. However,
the supplemental new drug application was  rejected by the Food
and Drug Administration (FDA) in 2012 as the risk-beneﬁt proﬁle
was deemed unfavorable [25]. An ongoing phase 3 trial is further
investigating decitabine in older patients with AML  (≥60 years;
NCT01633099); primary outcome measures are CR and survival
rates.
It is noteworthy that when using hypomethylating agents a
response may  not be evident until after several treatment cycles
[7]; in older (≥65 years) patients with newly diagnosed AML
treated with decitabine, the median time to best response for
patients achieving CR or CR with incomplete platelet recovery was
4.3 months [10]. This delay to response will naturally affect sur-
vival, since these patients remain at risk of fatal complications of
marrow failure.
Cytarabine, in addition to forming the backbone of intensive
induction therapy for the treatment of AML, can also be admin-
istered at reduced doses as a low-intensity treatment option [7].
Phase 3 evaluation of the safety and efﬁcacy of LDAC (vs pal-
liative therapy with hydroxyurea) in patients considered unﬁt
for intensive therapy demonstrated a better CR rate (18% vs 1%;
p = 0.00006) and an improved OS (odds ratio [OR] = 0.60, 95% con-
ﬁdence interval [CI]: 0.44–0.81; p = 0.0009) with LDAC, although
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here was no beneﬁt for patients with adverse cytogenetics [11].
n this trial, older AML patients could be randomized to the phase
 study of LDAC vs hydroxyurea vs more intensive chemotherapy
egimens. The vast majority of over 200 patients were assigned
o the low-intensity therapy (i.e., not randomized). The patients
ssigned to the low-intensity therapy tended to be older and
ave worse performance status, secondary leukemia and more
eart disease and documented comorbid conditions [11]. This
tudy suggests that trials comparing intensive versus non-intensive
herapies in unselected, older AML  patients may  be very dif-
cult to perform now due to patient and physician bias and
hoice.
In the USA, azacitidine and decitabine are the most com-
only used low-intensity therapies for patients with AML  [22].
n contrast, use of LDAC as monotherapy is not widely accepted
26] despite demonstrating an improved OS [11]. However, it
s generally well tolerated (vs treatment with best supportive
are), and can be administered in an outpatient or home care
etting [11]. Azacitidine and decitabine treatment is associated
ith myelosuppression, with cytopenias frequently reported as
dverse events (AEs) for both (Table 1) [9,10]. Myelosuppression
ypically occurs in the ﬁrst few treatment cycles and generally
mproves during subsequent cycles [27]. In contrast, phase 3 data
id not demonstrate any excess toxicity or increased transfu-
ion or other supportive care requirements with LDAC compared
ith hydroxyurea [11]. Most AEs with LDAC treatment were
ild/moderate in intensity; grade 3/4 events observed in the
rst 2 cycles included nausea/emesis, alopecia, oral toxicity, diar-
hea, and cardiac toxicity [11]. However, a comparative study of
DAC and azacitidine in high-risk MDS  (AZA001) which includes
atients with WHO-deﬁned AML  (≥20% blasts) has shown lower
ates of cytopenias and more rapid recovery with azacitidine
9].
The goals of currently available low-intensity therapies for older
atients are to achieve remission, prolong survival, and main-
ain quality of life (QoL). Currently, for the majority of older
ML  patients, treatment is primarily palliative and not curative,
ighlighting the unmet medical need in this group of patients
12,28]. For many patients unﬁt for intensive remission induc-
ion therapy, treatment choice is a balance between pursuing
ctive treatment for their disease while maintaining QoL [28],
nd, while they may  not offer a cure, survival following low-
ntensity treatment options is similar to that following more
ntensive therapies. A randomized multicenter trial comparing
DAC vs intensive chemotherapy in patients aged >65 years
ith de novo AML  demonstrated a higher CR rate with inten-
ive chemotherapy; however, with LDAC the number of early
eaths was reduced, and more durable partial remissions were
btained, resulting in comparable OS [29]. Further support for
he use of low-intensity vs intensive treatment approaches comes
rom a recent retrospective review of patients aged ≥65 years
ith newly diagnosed AML  treated at a single institution between
000 and 2010 with intensive chemotherapy compared with either
zacitidine- or decitabine-based therapy [30]. Although the CR rate
as higher with intensive chemotherapy compared with epige-
etic therapy, there was a trend for lower early mortality with
pigenetic therapy, and survival rates in the 2 groups were sim-
lar.
Although low-intensity therapies offer an active treatment
lternative to best supportive care for patients who  are unable
o tolerate intensive therapy, they are not curative [28]. Inter-
retation of survival data for these agents may  be confounded
y patients receiving standard chemotherapy after failure of a
ess intensive approach. Other limitations associated with these
herapies, such as delay to response, toxicities, and convenience
or patients, should also be considered when making treatmenth 39 (2015) 183–191
choices, and when evaluating potential combination partners for
novel agents. New approaches to treat older patients with AML  who
are ineligible for intensive therapy are urgently needed. However,
it is clear that the interpretation of trials of low-intensity therapy
will continue to be complicated by the lack of a prospective def-
inition of the “unﬁt” population and treatment choices following
an initial low-intensity therapy. Nevertheless, many clinical trials
are currently focused on the development of effective new com-
bination regimens for this group of patients. While combination
of currently recommended low-intensity agents is less attractive
due to similarities in their mechanisms of action and overlap-
ping safety proﬁles, there is much interest in the potential for
combining these ‘backbone’ low-intensity treatments with novel
therapies, and a number of early phase trials have reported promis-
ing results.
4. Novel treatment combinations in development for AML
Novel agents with diverse mechanisms of action are under
investigation in combination with LDAC and/or hypomethylating
agents for the treatment of older/unﬁt patients with newly diag-
nosed AML  (Table 2) [31–44]. Evaluation of a number of agents has
reached phase 2/3 or phase 3 development (Table 3).
4.1. Agents in phase 3 development
Data from clinical trials are available for gemtuzumab ozogam-
icin (GO) and tipifarnib in combination with LDAC. In addition,
ongoing trials are investigating barasertib plus LDAC, sapacitabine
plus decitabine, and volasertib plus LDAC in older patients with
newly diagnosed AML  considered unﬁt for intensive therapy.
Antibody-conjugated cytotoxic GO (Mylotarg) and the farnesyl-
transferase inhibitor tipifarnib (Zarnestra) were both investigated
in combination with LDAC in a ‘pick-a-winner’ trial design (NCRI
AML  16) [45,46]. Combined data for GO plus LDAC from the LRF AML
14 and NCRI AML  16 trials (N = 495, including 430 patients with
de novo or secondary AML) demonstrated an improved response
rate (CR or CR with incomplete blood count recovery [CRi]) for
GO plus LDAC compared with LDAC alone (30% vs 17%; OR = 0.48
[95% CI: 0.32–0.73]; p = 0.006), but no difference in 12-month OS
(27% vs 25%; hazard ratio = 0.99, [95% CI: 0.83–1.16]; p = 0.9). There
was also no difference in 30-day (18% vs 16%) or 8-week mortality
(29% vs 27%), but nausea/vomiting, gastrointestinal/liver toxic-
ity, and supportive care requirements were increased with the
addition of GO [45]. Parenthetically, a comparison of low-dose
clofarabine vs LDAC in this ‘pick-a-winner’ study also showed a
higher response rate with clofarabine, but no difference in overall
or disease-free survival [47]. These 2 studies have questioned the
value of CR as a surrogate marker for survival at least in this pop-
ulation of patients. The survival of patients who did not achieve
remission or relapsed after remission was  superior in the LDAC
arm compared to the GO/LDAC combination [45]. Similarly, the sur-
vival of patients treated with clofarabine who did not respond or
relapsed was inferior to the same populations treated with LDAC
[47]. These observations suggest that the toxicities associated with
initial therapy may undermine any potential survival advantage
despite achieving CR. The ability to respond to and to tolerate sub-
sequent therapy after relapse will also affect survival. Finally, it is
possible that the degree of response in the experimental arms of
these 2 studies was insufﬁcient to translate to an OS beneﬁt. In
the NCRI AML  16 trial (N = 65, including 54 patients with de novo
or secondary AML), the addition of tipifarnib to LDAC was found
to have no effect on response (CR/CRi rate, 18% vs 25%), toxicity
(30-day mortality, 12% vs 16%; 8-week mortality, 30% vs 25%) or
survival (12-month OS, 12% vs 34%) vs LDAC alone. Following data
H.P. Erba / Leukemia Researc
Table  2
Mechanism of action for novel agents in development as combination partners with
low-intensity therapies for older/unﬁt patients with AML.
Agent a Mechanism of action
Phase 3 (or phase 2/3)
Barasertib Aurora B kinase inhibitor; causes growth
arrest, and induces accumulation of cells with
4N/8N DNA content and apoptosis [31]
Gemtuzumab ozogamicin Antibody-conjugated cytotoxic; binds to the
CD33 antigen and is internalized leading to
intracellular release of calicheamicin, which
acts by causing DNA double strand breaks [32]
Sapacitabine Nucleoside analogue prodrug; active
metabolite is incorporated into DNA causing
single- and double-strand breaks and cell cycle
arrest in G2 phase [33,34]
Tipifarnib Farnesyltransferase inhibitor; exact
mechanism of action unknown, but targets
thought to include Ras with downstream
effects on cell proliferation and survival [35]
Volasertib Cell cycle kinase inhibitor; targets Polo-like
kinase (Plk) causing abnormal spindle
formation and cell cycle disruption leading to
polo arrest and apoptosis [36]
Phase 2
Bortezomib Proteosome inhibitor; causes Bcl-2
phosphorylation and cleavage leading to cell
cycle arrest in G2-M phase and apoptosis [37]
Clofarabine Nucleoside analogue prodrug; following
intracellular phosphorylation acts to impair
synthesis and repair of DNA and cause
apoptosis [38]
Lenalidomide Thalidomide derivative; acts via
immunomodulatory and antiangiogenic
effects, as well as direct cytotoxicity [39]
Tosedostat Aminopeptidase inhibitor; thought to exert
antiproliferative effects via inhibition of
protein recycling and subsequent depletion of
cellular amino acids [40]
Vorinostat HDAC inhibitor; induces accumulation of
acetylated histones and nonhistone proteins to
prevent proliferation and inhibit tumor growth
[41]
Phase 1
MLN4924 NAE inhibitor; disrupts cullin-RING
ligase-mediated protein turnover leading to
apoptosis via deregulation of S-phase DNA
synthesis [42]
PF-04449913 SMO  inhibitor; targets SMO  in the Hedgehog
signaling pathway, which is reported to
regulate processes such as tumor growth,
self-renewal, and chemotherapy resistance
[43]
Valproic acid HDAC inhibitor; induction of differentiation,
and antiproliferative/proapoptotic effects
reported in AML  [44]
a Highest phase of clinical development reached as combination therapy with
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Aow-intensity therapies for older/unﬁt patients with AML.
ML: acute myeloid leukemia: HDAC: histone deacetylase; NAE: NEDD8-activating
nzyme; SMO: smoothened.
eview of the ﬁrst 45 patients, this combination was determined to
e ineffective and closure of randomization to this treatment was
ecommended [46].
The Aurora kinase B inhibitor barasertib (AZD1152) is currently
nder phase 2/3 investigation in combination with LDAC. Phase 1
valuation of this combination in patients with newly diagnosed
ML aged ≥60 years ineligible for intensive induction therapy
N = 22) demonstrated a response rate of 45% (6 CR, 2 CRi, and 2 par-
ial remissions [PR]). Dose-limiting toxicities (DLTs) were reported
n 2 patients (both grade 3 stomatitis/mucositis), and the most com-
on  AEs were infection (73%), febrile neutropenia (59%), nausea
50%), and diarrhea (46%) [48]. This experience raises concern about
he toxicities associated with some targeted therapies. Since the
urora kinase B inhibitors are associated with mucositis, the beneﬁth 39 (2015) 183–191 187
of this class of agents over more intensive cytotoxic chemotherapy
regimens in this population is uncertain. The SPARK-AML1 phase
2/3 trial is further investigating barasertib in combination with
LDAC vs barasertib or LDAC alone in this setting (NCT00952588).
This trial is ongoing, although recruitment has been completed.
Data from stage 1 of this trial comparing the efﬁcacy, safety, and
tolerability of single-agent barasertib and LDAC have been reported
[49]; however, it does not appear that stage 2 of this trial has been
initiated and the clinical development of barasertib in AML  has been
discontinued.
Sapacitabine (CYC682), a nucleoside analogue prodrug whose
active metabolite is incorporated into DNA causing single and dou-
ble strand breaks, and cell cycle arrest in G2 phase [33,34], is
currently under investigation in combination with decitabine. Pre-
liminary data from a phase 1/2 trial of this combination in patients
aged ≥70 years with newly diagnosed AML  who  were consid-
ered unﬁt for intensive therapy (N = 25) demonstrated responses
in 9/25 patients (4 CR, 3 PR, and 2 major hematologic improve-
ments [HI] in platelets). No DLTs were observed; the most common
AEs included weakness, anorexia, nausea, constipation, diarrhea,
dyspnea, edema, pneumonia, febrile neutropenia, neutropenia,
thrombocytopenia, anemia, and hypocalcemia [50]. The SEAMLESS
trial (NCT01303796) is further investigating this combination vs
decitabine alone in this patient subgroup. Pooled analysis of the
lead-in part of this phase 3 study combined with phase 1/2 data
(N = 46) demonstrated a response rate of 37% for the combination
of sapacitabine and decitabine (10 CR, 2 PR, and 5 major HI), with
60-day mortality of 13% [51]. The primary endpoint for the phase
3 trial is OS, and secondary endpoints include CR, CR with incom-
plete platelet recovery, PR, and HI. The SEAMLESS trial is currently
recruiting patients, with an estimated completion of enrollment in
October 2014.
Volasertib (BI 6727), a selective and potent cell cycle kinase
inhibitor that induces mitotic arrest and apoptosis by targeting
Polo-like kinase 1, is currently under phase 3 investigation in com-
bination with LDAC [36]. In a phase 2 trial, volasertib plus LDAC has
shown improved efﬁcacy vs LDAC alone in previously untreated
patients with AML  considered ineligible for intensive remission
induction therapy (N = 87; median age, 75–76 years) [52]. A signiﬁ-
cantly greater proportion of patients who received the combination
treatment achieved CR or CRi compared with patients who received
LDAC alone (31.0% vs 13.3%; OR = 2.91; p = 0.052). Responses with
volasertib plus LDAC were seen across genetic groups, including
5/14 patients with adverse cytogenetics. Median event free survival
(EFS) was  longer in patients who  received volasertib plus LDAC
(5.6 vs 2.3 months; hazard ratio = 0.57 [95% CI: 0.35–0.92];
p = 0.021). Median OS was also prolonged with volasertib + LDAC
(8 vs 5.2 months; hazard ratio = 0.63 [95% CI: 0.40–1.00]; p = 0.047)
[52]. There was  an increased frequency of grade ≥3 non-
hematologic AEs with volasertib plus LDAC compared with LDAC,
especially for grade 3 gastrointestinal AEs (21% vs 7%), grade 3
febrile neutropenia (38% vs 7%), and grade 3 infections (38% vs 7%).
The increase in frequency of AEs seen with the addition of volasertib
was expected given its myelosuppressive mechanism of action, and
available data did not suggest an increase in early mortality with
volasertib plus LDAC vs LDAC (30-day, 60-day, and 90-day mor-
tality rates were 9.5% vs 8.9%, 21.4% vs 17.8%, and 28.6% vs 33.3%,
respectively) [52]. POLO-AML-2 (NCT01721876) is a double-blind
phase 3 study further evaluating the efﬁcacy, safety, and pharma-
cokinetics of volasertib plus LDAC vs placebo plus LDAC in patients
newly diagnosed with AML  aged ≥65 years, who are ineligible for
intensive remission induction therapy. The primary outcome mea-
sures are CR and CRi, and secondary outcome measures are OS,
EFS, and relapse-free survival. POLO-AML-2 is currently recruit-
ing patients with an estimated primary completion date of April
2016.
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Table  3
Summary of novel agents in phase 2 or phase 3 development in combination with currently recommended low-intensity treatments for older or unﬁt patients with newly
diagnosed AML.
Novel agent
Details of highest phase clinical trial to datea
StatusPhase (trial
identiﬁer)
Trial design
Comparator (s) Estimated enrolment Patient age
Azacitidine combined with:
Gentuzumab
ozogamicin
2 (NCT00658814) N/A N = 139 ≥60 years Ongoing, but not recruiting
Lenalidomide 2 (NCT01358734) Single-agent
lenalidomide
Single-agent
azacitidine
N = 120 ≥65 years Recruiting (no published
data available)
Vorinostat 2 (NCT00948064) Single-agent
azacitidine
N = 80 (including
patients with MDS)
≥18 years Recruiting (no published
data available)
Decitabine combined with:
Bortezomib 2 (NCT01420926
[CALGB 11002])
Single-agent decitabine N = 172 ≥60 years Ongoing, but not recruiting
(no published data
available)
Sapacitabine 3 (NCT01303796
[SEAMLESS])
Single-agent decitabine N = 485 ≥70 years Recruiting (no published
data available)
Tosedostat 2 (NCT01567059) Tosedostat + cytarabine N = 60 (including
patients with MDS)
≥18 years Recruitment is currently
suspended due to a partial
clinical hold being placed
on tosedostat by the FDA in
June 2013 [58]
LDAC combined with:
Barasertibb 2/3 (NCT00952588
[SPARK-AML1])
Single-agent barasertib
Single-agent LDAC
N = 417 ≥60 years Ongoing, but not recruiting
Clofarabine 2 (NCT00088218) Single-agent
clofarabine
N = 95 (included
patients with MDS)
≥60 years Completed
Gemtuzumab
ozogamicin
3  (NCT00005823
[LRF AML  14])
2/3 (NCT00454480
[NCRI AML  16])
Single-agent LDAC
Single-agent LDAC
N = 2000
N = 2000
(both trials included
patients with MDS;
‘pick-a-winner’ trial
design)
≥60 years (or <60 years
and unﬁt for intensive
therapy)
Unknown/completed
Tipifarnib 2/3 (NCT00454480
[NCRI AML  16])
Single-agent LDAC N = 2000 (included
patients with MDS;
‘pick-a-winner trial’
design)
≥60 years (or <60 years
and unﬁt for intensive
therapy)
Completed
Volasertib 3 (NCT01721876
[POLO-AML-2])
Placebo + LDAC N = 660 ≥65 years Recruiting (no published
data available)
A splast
4
b
t
n
a
P
a
c
1
g
≥
g
a
a
a
P
(
a
r
e
oa As listed on ClinicalTrials.gov.
b Clinical development in AML  has been discontinued.
ML: acute myeloid leukemia; FDA: Food and Drug Administration; MDS: myelody
.2. Agents in phase 2 development
Several novel agents (GO, lenalidomide, and vorinostat) have
een or are currently being evaluated in combination with azaci-
idine in phase 2 clinical trials for the treatment of patients with
ewly diagnosed AML  unﬁt for intensive therapy.
The combination of GO and azacitidine has been investigated in
 phase 2 trial of patients aged ≥60 years (NCT00658814, N = 137).
atients were stratiﬁed into good-risk (n = 79 evaluable patients)
nd poor-risk (aged ≥70 years and performance status 2 or 3, n = 54)
ohorts. CR/CRi rates were 44% and 35%, respectively, and OS was
1 months and 6 months. Thirty-day mortality was 8% and 14%. In
ood-risk patients, the main non-hematologic toxicity was  grade
3 neutropenic fever (33%); in poor-risk patients, 57% experienced
rade 3/4 toxicities. This study determined that it was  possible to
dminister this treatment in an outpatient setting for both good-
nd poor-risk patients [53,54].
A phase 2 evaluation of lenalidomide plus azacitidine in patients
ged ≥65 years is currently recruiting patients (NCT01358734).
hase 1/2 data for this combination in patients aged ≥60 years
N = 42) has shown an overall response rate of 41% (19% CR, 9% CRi,
nd 12% PR), and median OS of 20 weeks. Grade ≥3 toxicities were
elatively uncommon, and most frequent AEs were gastrointestinal
vents, fatigue, or myelosuppression. Early death (within 28 days
f the start of treatment) occurred in 17% of patients [55].ic syndromes.
Vorinostat in combination with azacitidine is currently under
investigation in a phase 2 trial (≥18 years, and including patients
with MDS; NCT00948064). Available phase 2 data for this combi-
nation in patients with previously untreated MDS  or AML  (median
age 74 years; N = 30, including 12 with AML) demonstrated a
response rate of 30% (8 CR and 1 complete marrow response), and
median survival of 7 months. One patient developed severe non-
hematologic toxicity (nausea, vomiting), and 1 patient died during
induction therapy; 80% of patients survived >60 days [56].
There are 2 ongoing phase 2 trials evaluating decitabine
combinations in this setting. Tosedostat is an orally bioavail-
able aminopeptidase inhibitor with single-agent activity in older
patients with relapsed and refractory AML  [57]. A phase 2 trial
evaluating tosedostat plus decitabine vs tosedostat plus cytara-
bine (NCT01567059) was suspended due to a partial clinical
hold being placed on tosedostat by the FDA in June 2013 [58].
However, the clinical hold was  removed in January 2014, and
clinical trials are proceeding. Phase 2 evaluation of the protea-
some inhibitor bortezomib in combination with decitabine is also
ongoing (NCT01420926 [CALGB 11002]). Phase 1 data for this com-
bination in patients aged ≥65 years (N = 19, including 10 with
previously untreated AML) demonstrated a CR/CRi rate of 50% (3 CR,
1 CRi, and 1 unconﬁrmed CR) in patients with previously untreated
AML. Two  patients with previously untreated AML  died within
8 weeks of treatment. No hematologic DLTs were observed, but
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rade ≥3 infections or febrile neutropenia were common (11/19
atients), and bortezomib-related neuropathy was observed after
epeated treatment cycles [59].
Phase 2 data for clofarabine combined with LDAC (n = 54) com-
ared with single-agent clofarabine (n = 16) have been reported.
his study included patients with AML  or MDS  aged ≥60 years;
6/70 patients were newly diagnosed with AML. The CR/CRi rate
as higher with clofarabine plus LDAC vs clofarabine alone (67% vs
1%; p = 0.012). Due to the Bayesian design and increased number
f induction deaths with single-agent clofarabine in the early part
f this randomized phase 2 study, only 16 patients were accrued to
he single-agent arm. The explanation of the increased induction
ortality with single-agent clofarabine compared with the combi-
ation regimen was not apparent. Median OS was 11.4 months vs
.8 months (p = 0.10), and median EFS was 7.1 months vs 1.7 months
p = 0.04). The most frequent non-hematologic AEs were gastroin-
estinal and hepatic, and grade 3 myelosuppression was ubiquitous
uring treatment. Early death (within 14 days of the start of treat-
ent) occurred in 4% vs 19% of patients, and 19% vs 31% of patients
ied during the ﬁrst treatment course (p = 0.276) [26].
.3. Agents in phase 1 development
In addition to the novel combinations in phase 2 or 3 devel-
pment for the treatment of newly diagnosed AML  in older
atients ineligible for intensive therapy, several phase 1 trials
re also underway in this setting. Currently this includes the
EDD8-activating enzyme (NAE) inhibitor MLN4924 combined
ith azacitidine (NCT01814826), the hedgehog inhibitor PF-
4449913 in combination with LDAC (NCT01546038), and valproic
cid plus all-trans retinoic acid (ATRA) and LDAC (NCT00995332).
f these trials, data for the valproic acid/ATRA/LDAC combination
N = 36; median age 77 years) have been reported. This combination
emonstrated anti-leukemic activity with 2 patients (6%) achieving
 CR and stable disease in 9 patients [60].
.4. Summary of ongoing clinical development
Efﬁcacy results from clinical trials evaluating novel agents in
ombination with azacitidine, decitabine, or LDAC for the treat-
ent of older and/or unﬁt patients with newly diagnosed AML
ave been variable. Reported CR/CRi rates for the different com-
inations range from 18% for tipifarnib combined with LDAC [46]
o 67% for clofarabine administered in combination with LDAC [26].
here data for comparator arms are available, no trial has yet
emonstrated a signiﬁcant improvement in OS for a novel agent in
ombination with low-intensity therapies. However, 2 agents, clo-
arabine and volasertib, have been reported to increase EFS when
ombined with LDAC compared with treatment with clofarabine
r LDAC alone [26,52]. Toxicity is also a key consideration when
eveloping novel combination therapies for older, unﬁt patients.
arly mortality (usually deﬁned as within 30–60 days of the start
f treatment) has been generally comparable for the various novel
ombinations, ranging between approximately 10% and 20%, and
o signiﬁcant increases in early mortality have been reported with
he addition of a novel agent to single-agent, low-intensity therapy.
. Conclusions, expert opinion, and perspective
A number of considerations are important for future investiga-
ion of optimal combination therapies for the treatment of older
atients unﬁt for intensive therapy. Of critical importance is to
ave an adequate deﬁnition for the term ‘unﬁt for chemotherapy’.
nderstanding of the disease biology, as well as the prognostic
actors associated with the host, enables better determination of
hich patients are likely to beneﬁt from standard therapy andh 39 (2015) 183–191 189
which require alternative approaches. Objective scoring systems
are being developed to enable clearer identiﬁcation of patients unﬁt
for intensive therapy [61]. Treatment goals for this subgroup of
patients unﬁt for intensive therapy differ from those able to tol-
erate aggressive treatment with intensive therapy, and are more
focused on avoiding extended hospitalization in order to maintain
QoL. Importantly, some patients may  also wish to pursue some
form of active treatment for their disease with a view to achiev-
ing CR and improving survival [28]. The nature of these individual
treatment goals will impact on acceptable toxicity. The minimum
efﬁcacy for success for low-intensity treatments may  also differ
from that used as a benchmark in trials of more intensive therapies,
and will obviously need to take into account the efﬁcacy of exist-
ing low-intensity options. Investigators may  also wish to consider
the prognosis of the patient subgroup(s) they are treating, based
on factors such as comorbidities and cytogenetic risk group, when
determining appropriate efﬁcacy outcome measures. Assessment
of cognitive and physical function using available geriatric assess-
ment tools may  also help to prospectively deﬁne the subset of older
patients receiving less intensive therapy.
Selection of clinically meaningful endpoints is also key in assess-
ing the clinical value of novel therapies, as CR may  not translate to
a survival beneﬁt as seen in the MRC  experience [45]. Selection of
the traditional endpoint of OS may  not reﬂect the impact of a novel
treatment on patients’ QoL, while focusing on the CR rate could
overlook the potential for HI and subsequent survival beneﬁt or
enhanced QoL. The use of ‘less-than-CR’ measures such as CRi may
also be appropriate for some trials [62], although the deﬁnition of
CRi must be made clearer and used consistently in clinical trials.
Patients achieving CRi should become transfusion-independent,
but this is not a criterion used in the Cheson et al. deﬁnition [63]. CRi
must be clearly deﬁned as either incomplete neutrophil recovery or
incomplete platelet count recovery, not both. Otherwise, CRi may
not be any different from a morphologic leukemia-free state, which
is of unknown, but likely limited, clinical beneﬁt for patients. Col-
lection of health care resource utilization data could also be useful,
and evaluate not only economic beneﬁt, but also provide valuable
insight into patient QoL.
Finally, AML  is a heterogeneous disease and this remains
true in older, unﬁt patients who  vary by both patient-speciﬁc
and disease-speciﬁc factors, including cytogenetics and molecular
genetics. Dependent upon their mechanism of action, novel ther-
apies may  be more or less effective in particular biologic subsets
of patients. Although this seems obvious, it may  be difﬁcult to
determine clinical beneﬁt of a targeted therapy in a small sub-
set of patients in a large phase 3 trial [12]. There is currently
little data available regarding the role of single gene mutations
in older patients with AML, not to mention the interaction of
various genetic and epigenetic changes in individual patients. Con-
sequently, none of the targeted agents discussed in this review
are being tested in a selected population of AML  patients with a
speciﬁc biomarker. However, the therapeutic triumph achieved by
targeting the PML/RAR alpha fusion protein with arsenic trioxide
and all trans-retinoic acid in acute promyelocytic leukemia sug-
gests rational drug development based on a thorough knowledge
of the disease biology is a realistic goal. Only then will we be able
to resolve the unmet need of efﬁcacious and tolerable therapy for
older, unﬁt AML  patients.
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